Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. reduced its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 38.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,650 shares of the biotechnology company’s stock after selling 52,528 shares during the period. Victory Capital Management Inc.’s holdings in Exelixis were worth $2,786,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in EXEL. Principal Securities Inc. grew its stake in Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 373 shares during the last quarter. USA Financial Formulas purchased a new stake in Exelixis during the 4th quarter valued at about $32,000. Kestra Investment Management LLC purchased a new stake in Exelixis during the 4th quarter valued at about $39,000. UMB Bank n.a. grew its stake in Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 553 shares during the last quarter. Finally, V Square Quantitative Management LLC grew its stake in Exelixis by 37.3% during the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 425 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Price Performance

Shares of Exelixis stock opened at $36.65 on Monday. The business has a 50 day simple moving average of $35.36 and a two-hundred day simple moving average of $32.53. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $40.02. The stock has a market capitalization of $10.26 billion, a P/E ratio of 20.71, a PEG ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. As a group, research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on EXEL shares. Stephens restated an “equal weight” rating and issued a $29.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. Oppenheimer downgraded Exelixis from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. UBS Group upped their target price on Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Barclays upped their target price on Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Finally, Guggenheim restated a “buy” rating and issued a $42.00 target price on shares of Exelixis in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Exelixis presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.59.

Insider Activity at Exelixis

In related news, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the sale, the executive vice president now owns 303,310 shares of the company’s stock, valued at approximately $11,216,403.80. This trade represents a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary C. Beckerle sold 12,210 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares of the company’s stock, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 140,343 shares of company stock valued at $5,177,234. 2.85% of the stock is currently owned by insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.